Table 3. Subgroup analyses.
| OS | |||||
|---|---|---|---|---|---|
| Study characteristics | Datasets number | HR (95% CI) | I2 | P for subgroup effect | P for subgroup difference |
| Ethnicity | |||||
| Non-Asian | 7 | 1.28 [1.01, 1.61] | 0% | 0.04 | |
| Asian | 5 | 1.80 [0.67, 4.81] | 78% | 0.24 | 0.50 |
| Sample size | |||||
| >80 | 5 | 1.45 [1.12, 1.89] | 0% | 0.005 | |
| ≤80 | 7 | 1.39 [0.73, 2.64] | 67% | 0.32 | 0.89 |
| WHO grade | |||||
| II–III | 2 | 2.99 [1.52, 5.89] | 0% | 0.002 | |
| IV | 8 | 1.26 [0.76, 2.08] | 55% | 0.37 | 0.03 |
| CD44 detection method | |||||
| IHC | 6 | 1.21 [0.75, 1.95] | 52% | 0.45 | |
| qRT-PCR | 6 | 1.72 [1.03, 2.89] | 57% | 0.04 | 0.32 |
| CD44 cutoff | |||||
| IHC | 8 | 1.63 [0.86, 3.08] | 69% | 0.14 | |
| qRT-PCR | 4 | 1.33 [1.02, 1.74] | 0% | 0.03 | 0.57 |
| HR estimation | |||||
| Survival curve | 4 | 1.41 [1.06, 1.87] | 4% | 0.02 | |
| Reported | 8 | 1.41 [0.81, 2.46] | 63% | 0.22 | 0.99 |
| Survival analysis | |||||
| Multivariate | 7 | 1.68 [1.06, 2.64] | 35% | 0.03 | |
| Univariate | 5 | 1.20 [0.72, 2.01] | 67% | 0.49 | 0.34 |
| Median follow-up duration | |||||
| >20 months | 6 | 1.46 [0.97, 2.20] | 42% | 0.07 | |
| ≤20 months | 6 | 1.40 [0.77, 2.54] | 64% | 0.28 | 0.90 |